Medical

For brain cancer, the major obstacle to treatment is not the tumour, but the brain itself. How to break the "blood-brain barrier" and allow effective anti-cancer drugs to enter the brain to take effect has long been a key issue in brain cancer treatment. Recently, a new study has shown that a new type of pump can be implanted in brain cancer patients to safely break the blood-brain barrier and better treat brain cancer!

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

Who is CinCor?

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

At present, test tube babies are divided into a generation of test tube babies according to popular parlance, namely conventional in vitro fertilization embryo transfer (IVF-ET); The second generation of test tube infants, namely intracytoplasmic sperm injection (ICSI); The third generation of test tube infants, namely, pre implantation genetic testing (PGT).

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

With the continuous development of science and technology, a series of new myopia correction operations have emerged in the field of ophthalmology. After surgery, myopia patients can also achieve the vision effect when wearing glasses without wearing glasses. Excimer laser surgery, which has been carried out in the last two decades, has the advantages of high efficiency, accuracy and safety.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!